What makes clinical research ethical?

JAMA

Volumn 283, Issue 20, 2000, Pages 2701-2711

  Emanuel, Ezekiel J ^a   Wendler, David ^a   Grady, Christine ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL RESEARCH; HUMAN; INFORMED CONSENT; MEDICAL ETHICS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

EID: 0034737962     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.20.2701     Document Type: Article

References (130)

1. Childress J. The place of autonomy in bioethics. Hastings Cent Rep. 1984;14:12-16.
2. Dworkin G. The Theory and Practice of Autonomy. New York, NY: Cambridge University Press; 1988.
3. Beauchamp TL, Childress J. The Principles of Biomedical Ethics. New York, NY: Oxford University Press; 1996:chap 3.
4. Vanderpool HY, ed. The Ethics of Research Involving Human Subjects. Frederick, Md: University Publishing Group; 1996:45-58.
5. Freedman B. Scientific value and validity as ethical requirements for research. IRB. 1987;9:7-10.
6. Office of the Secretary. Protection of human subjects: informed consent and waiver of informed consent requirements in certain emergency research; final rules. 61 Federal Register 51498-51533 (1996).
7. Truog RD, Robinson W, Randolph A, Morris A. Is informed consent always necessary for randomized, controlled trials? N Engl J Med. 1999;340:804-807.
8. US Department of Health and Human Services. Protections of human subjects. 45 CFR §46 (1991).
9. Angell M. The ethics of clinical research in the third world. N Engl J Med. 1997;337:847-849.
10. Lurie P, Wolfe S. Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. N Engl J Med. 1997;337:853-856.
11. Varmus H, Satcher D. Ethical complexities of conducting research in developing countries. N Engl J Med. 1997;337:1003-1005.
12. Grady C. Science in the service of healing. Hastings Cent Rep. 1998;28:34-38.
13. Crouch R, Arras J. AZT trials and tribulations. Hastings Cent Rep. 1998;28:26-34.
14. Rothman KJ, Michels KB. The continuing unethical use of placebo controls. N Engl J Med. 1994;331: 394-398.
15. Freedman B. Placebo-controlled trials and the logic of clinical purpose. IRB. 1990;12:1-6.
16. Weijer C. Placebo-controlled trials in schizophrenia. Schizophr Res. 1999;35:211-218.
17. Lipsett M. On the nature and ethics of phase I clinical trials of cancer chemotherapies. JAMA. 1982; 248:941-942.
18. Freedman B. Cohort-specific consent. IRB. 1990; 12:5-7.
19. Annas GJ. The changing landscape of human experimentation. Health Matrix. 1992;2:119-140.
20. Lehrman S. Jewish leaders seek guidelines. Nature. 1997;389:322.
21. Levine C, Dubler NN, Levine RJ. Building a new consensus. IRB. 1991;13:1-17.
22. Weijer C, Goldsand G, Emanuel EJ. Protecting communities in research. Nat Genet. 1999;23:275-280.
23. Juengst ET. Groups as gatekeepers to genomic research. Kennedy Institute J Ethics. 1998;8:183-200.
24. Weijer C. Protecting communities in research. Camb Q Healthc Ethics. 1999;8:501-513.
25. Kopelman LM, Moskop JC, eds. Children and Health Care. Dordrecht, the Netherlands: Klumer; 1989:73-87.
26. Freedman B, Fuks A, Weijer C. In loco parentis. IRB. 1993;15:13-19.
27. Leikin S. Minors' assent, consent, or dissent to medical research. IRB. 1993;15:1-7.
28. Grodin MA, Glantz LH, eds. Children as Research Subjects. New York, NY: Oxford University Press; 1994:81-101.
29. Committee on Drugs, American Academy of Pediatrics. Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics. 1995;95:286-294.
30. Levine RJ. Ethics and Regulation of Clinical Research. 2nd ed. New Haven, Conn: Yale University Press; 1988.
31. The President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. Summing Up. Washington, DC: US Government Printing Office; 1983.
32. Katz J. Experimentation With Human Beings. New York, NY: Russell Sage Foundation; 1972.
33. Wertheimer A. Exploitation. Princeton, NJ: Princeton University Press; 1996: chap 1.
34. DeCastro LD. Exploitation in the use of human subjects for medical experimentation. Bioethics. 1995; 9:259-268.
35. The Nuremberg Code. JAMA. 1996;276:1691.
36. World Medical Association. Declaration of Helsinki. JAMA. 1997;277:925-926.
37. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report. Washington, DC: US Government Printing Office; 1979.
38. Council for International Organizations of Medical Sciences. International Ethical Guidelines for Biomedical Research Involving Human Subjects. Geneva, Switzerland: CIOMS; 1993.
39. Brody BS. The Ethics of Biomedical Research. New York, NY: Oxford University Press; 1998:chap 9.
40. Fluss S. International Guidelines on Bioethics. Geneva, Switzerland: European Forum on Good Clinical Practice/CIOMS; 1998.
41. Sugarman J, Mastroianni A, Kahn JP. Research With Human Subjects. Frederick, Md: University Publishing Group; 1998.
42. World Health Organization. Guidelines for good clinical practice for trials on pharmaceutical products. In: The Use of Essential Drugs. Appendix 3. Geneva, Switzerland: WHO; 1995.
43. Council of Europe (Direcorate of Legal Affairs). Convention for the Protection of Human Rights and Dignity of the Human Being With Regard to the Application of Biology and Medicine. Strasbourg, France: Council of Europe; 1996.
44. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Good clinical practice: consolidated guidance, 62 Federal Register 25692 (1997).
45. European Forum for Good Clinical Practice. Guidelines and Recommendations for European Ethics Committees. Leuven, Belgium: EFGCP; 1997.
46. Medical Research Council (UK). Guidelines for Good Clinical Practice in Clinical Trials. London, England: MRC; 1998.
47. Uganda National Council of Science and Technology (UNCST). Guidelines for the Conduct of Health Research Involving Human Subjects in Uganda. Kampala, Uganda: UNCST; 1998.
48. Medical Research Council of Canada, Natural Sciences and Engineering Research Council of Canada, and Social Sciences and Humanities Research Council of Canada. Tri-Council Policy Statement. Ottawa, Ontario: Public Works and Government; 1998.
49. National Health and Medical Research Council. National Statement on Ethical Conduct in Research Involving Humans. Canberra, Australia: NHMRC; 1999.
50. Levine RJ. The impact of HIV infection on society's perception of clinical trials. Kennedy Institute J Ethics. 1994;4:93-98.
51. Vanderpool HY, ed. The Ethics of Research Involving Human Subjects. Frederick, Md: University Publishing Group; 1996:235-260.
52. Levine RJ. The need to revise the Declaration of Helsinki. N Engl J Med. 1999;341:531-534.
53. Jones J. Bad Blood. New York, NY: Free Press; 1992.
54. Rothman D, Rothman S. The Willowbrook Wars. New York, NY: Harper & Row; 1984.
55. Krugman S. The Willowbrook hepatitis studies revisited. Rev Infect Dis. 1986;8:157-162.
56. Advisory Committee on Human Radiation Experiments. The Human Radiation Experiments. New York, NY: Oxford University Press; 1996.
57. Christakis N, Panner M. Existing international ethical guidelines for human subjects. Law Med Health Care. 1991;19:214-220.
58. Lasagna L. The Helsinki declaration. J Clin Psychopharmacol. 1995;15:96-98.
59. Glantz LH, Annas GJ, Grodin MA, et al. Research in developing countries. Hastings Cent Rep. 1998;28:38-42.
60. Committee on the NIH Research Priority-Setting Process. Scientific Opportunities and Public Needs. Washington, DC: National Academy Press; 1998.
61. Rutstein DD. The ethical design of human experiments. In: Fruend PA, ed. Experimentation With Human Subjects. New York, NY: Braziller Library; 1970: 383-402.
62. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Appendix. Vol 1. Washington, DC: US Government Printing Office; 1978:chap 9.
63. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987;317:141-145.
64. National Institutes of Health. NIH policy and guidelines on the inclusion of children as participants in research involving human subjects. Available at: http://grants.nih.gov/grants/guide/notice-files/not98-024.html. Accessed April 28, 2000.
65. Dresser R. Wanted: single, white male for medical research. Hastings Cent Rep. 1992;22:21-29.
66. Merton V. The exclusion of pregnant, pregnable, and once pregnable (a.k.a. women) from biomedical research. Am J Law Med. 1993;19:369-451.
67. DeBruin D. Justice and the inclusion of women in clinical studies. Kennedy Institute J Ethics. 1994;4: 117-146.
68. Mastriani AC, Faden RR, Federman DD. Women and Health Research. Washington, DC: National Academy Press; 1994.
69. Vanderpool HY, ed. The Ethics of Research Involving Human Subjects. Frederick, Md: University Publishing Group; 1996:105-126.
70. Weijer C. Evolving issues in the selection of subjects for clinical research. Camb Q Healthc Ethics. 1996; 5:334-345.
71. Weijer C, Fuks A. The duty to exclude. Clin Invest Med. 1994;17:115-122.
72. Merkatz RB, Temple R, Sobel S, et al. Women in clinical trials of new drugs. N Engl J Med. 1993;329: 292-296.
73. National Institutes of Health. NIH Guidelines for the inclusion of women and ethnic minorities in research, 59 Federal Register 14508-14513 (1994).
74. Barry M, Molyneux M. Ethical dilemmas in malaria drug and vaccine trials. J Med Ethics. 1992;18: 189-192.
75. Kahn J, Mastroianni A, Sugarman J. Beyond Consent. New York, NY: Oxford University Press; 1998.
76. Annas G, Grodin M. Human rights and maternal-fetal HIV transmission prevention trials in Africa. Am J Public Health. 1998;88:560-563.
77. Freedman B, Fuks A, Weijer C. Demarcating research and treatment. Clin Res. 1992;40:653-660.
78. Anderson E. Value in Ethics and Economics. Cambridge, Mass: Harvard University Press; 1993:chap 9.
79. Weijer C. Thinking clearly about research risks. IRB. 1999;21:1-5.
80. Sen A, Williams B, eds. Utilitarianism and Beyond. Cambridge, England: Cambridge University Press; 1982.
81. MacLean D, ed. Values at Risk. Totowa, NJ: Rowman & Allanheld; 1985:31-48.
82. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
83. Sen A. Choice, Welfare, and Measurement. Cambridge, Mass: Harvard University Press; 1982:264-284.
84. Relman AS. Economic incentives in clinical investigations. N Engl J Med. 1989;320:933-934.
85. Porter RJ, Malone TE. Biomedical Research. Baltimore, Md: Johns Hopkins University Press; 1992.
86. Thompson D. Understanding financial conflicts of interest. N Engl J Med. 1993;329:573-576.
87. Spece RG, Shimm DS, Buchanan AE. Conflicts of Interest in Clinical Practice and Research. New York, NY: Oxford University Press; 1996.
88. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. Institutional Review Boards. Washington, DC: US Government Printing Office; 1978.
89. Curran WJ. Government regulation of the use of human subjects in medical research. In: Freund PA, ed. Experimentation With Human Subjects. New York, NY: George Braziller; 1970:402-455.
90. Edgar H, Rothman D. The institutional review board and beyond. Milbank Q. 1995;73:489-506.
91. Moreno J, Caplan AL, Wolpe PR, et al. Updating protections for human subjects involved in research. JAMA. 1998;280:1951-1958.
92. Fried C. Medical Experimentation. New York, NY: American Elsevier Co; 1974.
93. Freedman B. A moral theory of informed consent. Hastings Cent Rep. 1975;5:32-39.
94. President's Commission for the Study of Ethical Problems in Medicine and Biomedical Research. Making Health Care Decisions. Washington, DC. US Government Printing Office; 1982.
95. Katz J. Human experimentation and human rights. St Louis University Law J. 1993;38:1-54.
96. Donagan A. Informed consent in therapy and experimentation. J Med Philos. 1977;2:318-329.
97. Faden RR, Beauchamp TL. A History and Theory of Informed Consent. New York, NY: Oxford University Press; 1986:chap 5-9.
98. Applebaum PA, Lidz CW, Meisel A. Informed Consent. New York, NY: Oxford University Press; 1987.
99. Grisso R, Applebaum PS. Assessing Competence to Consent to Treatment. New York, NY: Oxford University Press; 1998.
100. Buchanan AE, Brock DW. Deciding for Others. New York, NY: Cambridge University Press; 1990: chap 2.
101. American College of Physicians. Cognitively impaired subjects. Ann Intern Med. 1989;111:843-848.
102. Dresser R. Mentally disabled research subjects. JAMA. 1996;276:67-72.
103. National Bioethics Advisory Commission. Research Involving Persons With Mental Disorders That May Affect Decisionmaking Capacity. Washington, DC: US Government Printing Office; 1998.
104. Michels R. Are research ethics bad for our mental health? N Engl J Med. 1999;340:1427-1430.
105. Capron AM. Ethical and human rights issues in research on mental disorders that may affect decision-making capacity. N Engl J Med. 1999;340:1430-1434.
106. Weijer C, Shapiro S, Fuks A, Glass KC, Skrutkowska M. Monitoring clinical research. CMAJ. 1995; 152:1973-1980.
107. Biros MH, Lewis R, Olson C, et al. Informed consent in emergency research. JAMA. 1995;273:1283-1287.
108. Levine RJ. Research in emergency situations. JAMA. 1995;273:1300-1302.
109. Council on Ethical and Judicial Affairs, American Medical Association. Waiver of Informed Consent for Emergency Research CEJA Report 1-A-7, June 1997.
110. Macklin R. Against Relativism. New York, NY: Oxford University Press; 1999.
111. Scanlon TM. What We Owe to Each Other. Cambridge, Mass: Harvard University Press; 1999: chap 1, 8.
112. Kymlicka W. Liberalism, Community and Culture. New York, NY: Oxford University Press; 1989.
113. Angell M. Ethical imperialism? N Engl J Med. 1988;319:1081-1083.
114. Levine RJ. Informed consent. Law Med Health Care. 1991;19:207-213.
115. Ijsselmuiden CB, Faden RR. Research and informed consent in Africa. N Engl J Med. 1992;326: 830-833.
116. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med. 1990;322:810-816.
117. Gandara DR, Harvey WH, Monaghan GG, et al. The delayed-emesis syndrome from cisplatin. Semin Oncol. 1992;19:67-71.
118. Beck TM, Ciociola AA, Jones SE, et al. Efficacy of oral ondansetron in the prevention of emesis in out-patients receiving cyclophosphamide-based chemotherapy. Ann Intern Med. 1993;118:407-413.
119. Temple R. Government viewpoint of clinical trials. Drug Inform J. 1982;1610-1617.
120. Marty M, Pouillart P, Scholl S, et al. Comparison of 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med. 1990;322:816-821.
121. Hainsworth J, Harvey W, Pendergrass K, et al. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol. 1991;9:721-728.
122. Ondansetron and cisplatin-induced nausea and vomiting. N Engl J Med. 1990;323:1486.
123. Hait WN. Ondansetron and cisplatin-induced nausea and vomiting. N Engl J Med. 1990;323:1485-1486.
124. Citron ML. Placebos and principles. Ann Intern Med. 1993;118:470-471.
125. Rennels MB, Glass RI, Dennehy PH, et al. Safety and efficacy of high dose rhesus-human reassortant rotavirus vaccines. Pediatrics. 1996;97:7-13.
126. Bernstein DK, Glass RI, Rodgers G, et al. Evaluation of rhesus rotavirus monovalent and tetravalent reassortment vaccines in US children. JAMA. 1995; 273:1191-1196.
127. Joensuu J, Koskenniemi E, Pang XL, Vesikari T. Randomized placebo-controlled trial of rhesushuman reassortment rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet. 1997; 350:1205-1209.
128. Intussusception among recipients of rotavirus vaccine - United States, 1998-1999. MMWR Morb Mortal Wkly Rep. 1999;48:577-581.
129. Bern C, Martines J, de Zoysa I, Glass RI. The magnitude of the global problem of diarrheal disease. Bull World Health Organ. 1992;70:705-714.
130. Bresee JS, Glass RI, Ivanoff B, Gentsch JR. Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Vaccine. 1999;17:2207-2222.